Full video transcriptClick to expand
Auto-generated transcript of @drmaryclaire's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00So I see this a lot. I've seen it hundreds of times in the comments on the video and I know from my professional practice that
- 0:10millions of you are having issues with your libido. I'm just gonna say it and
- 0:14Here's the deal. It's really complicated and there's not a quick fix for most women because our
- 0:21libidos are
- 0:23More emotional than physical for the most part. I
- 0:26Don't consider myself an expert. I was taught nothing about the female libido in my residency and training. However, I have made friends with someone
- 0:34Who is her name is dr. Kelly Kasperson and she is a urologist who specializes in female sexual
- 0:41Dysfunction. I'm gonna drop a link in the comments to her Instagram and to some of the
- 0:46Programs that she offers to help women in this position
- 0:49Check her out and make sure you like the comments what stays on the top
Testosterone for women's libido: what the evidence actually shows
Quick answer
This video addresses hypoactive sexual desire disorder (HSDD) and female sexual interest and arousal disorder (FSIAD) in women over 35, a population where both psychological and hormonal contributors are clinically significant. The creator appropriately flags complexity and defers to specialist care rather than recommending a specific intervention. For perimenopausal patients, clinical workup should include both hormonal assessment and evaluation of relational, psychological, and medication-related factors before a treatment plan is established.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Testosterone for women's libido: what the evidence actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Testosterone for women's libido: what the evidence actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Testosterone for women's libido: what the evidence actually shows" from The 'Pause Life. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video addresses hypoactive sexual desire disorder (HSDD) and female sexual interest and arousal disorder (FSIAD) in women over 35, a population where both psychological and hormonal contributors are clinically significant.
The reason this review is not generic is the source wording and the canonical claim label "trt reply to mchllbeauty rn libido women over35 over40 over35clu." In this clip, the useful excerpt is: "So I see this a lot." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This video addresses hypoactive sexual desire disorder (HSDD) and female sexual interest and arousal disorder (FSIAD) in women over 35, a population where both psychological and hormonal contributors are clinically significant.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video addresses hypoactive sexual desire disorder (HSDD) and female sexual interest and arousal disorder (FSIAD) in women over 35, a population where both psychological and hormonal contributors are clinically significant. The creator appropriately flags complexity and defers to specialist care rather than recommending a specific intervention. For perimenopausal patients, clinical workup should include both hormonal assessment and evaluation of relational, psychological, and medication-related factors before a treatment plan is established.
- Basson (2001) established that many women experience 'responsive' rather than spontaneous desire, supporting the emotional component of female libido, but this model does not apply universally.
- Brotto et al. (2016, Journal of Sexual Medicine) confirmed that both spontaneous and responsive desire exist across women, and physical factors including hormones and medications contribute significantly.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Basson (2001) established that many women experience 'responsive' rather than spontaneous desire, supporting the emotional component of female libido, but this model does not apply universally.
- Brotto et al. (2016, Journal of Sexual Medicine) confirmed that both spontaneous and responsive desire exist across women, and physical factors including hormones and medications contribute significantly.
- Testosterone levels decline steadily in women from their 20s onward. A 2019 Cochrane review (Islam et al.) found low-dose testosterone improved sexual function in postmenopausal women, though no FDA-approved female testosterone product currently exists in the U.S.
- Fewer than 30% of OB-GYN residency programs in a 2019 Sexual Medicine survey included structured curricula on female sexual dysfunction, making the creator's admitted knowledge gap a systemic problem, not an individual failure.
- Shifren et al. (2008, Obstetrics and Gynecology) estimated that 26-43% of U.S. women experience low sexual desire depending on age group, confirming the scale of the issue the creator described.
- For perimenopausal and postmenopausal women specifically, declining estradiol affects genital blood flow and tissue sensitivity through direct physiological mechanisms, meaning emotional-only framings may delay appropriate hormonal evaluation.
- Any evaluation for low libido in women should include hormonal panel review, medication side effect assessment (especially SSRIs and hormonal contraceptives), pelvic floor evaluation, and psychological or relational factors, not one to the exclusion of others.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drmaryclaire actually say?
In a reply video responding to a comment about low libido, @drmaryclaire made two core claims: that female libido is "more emotional than physical for the most part," and that she was taught essentially nothing about female sexual dysfunction during her residency training. She didn't pitch a product or protocol. She admitted her own knowledge gaps and pointed viewers toward a urologist who specializes in the area. That's a pretty reasonable thing to do.
She also framed low libido as "really complicated" with "not a quick fix for most women." That framing matters because the comment sections of health TikTok are full of people selling exactly the opposite message. No claims about testosterone, no supplement recommendations, no dose talk. Just an honest referral.
Does the science back this up?
The emotional-versus-physical framing is broadly supported, but it's more complicated than a clean split. Yes, the research backs her general direction. But calling it a settled fact oversimplifies an active debate in sexual medicine.
The most widely cited model supporting her claim is Rosemary Basson's circular model of female sexual response (Basson, 2001, Journal of Sex and Marital Therapy), which argues that women often enter sexual encounters from a position of "responsive desire" driven by emotional intimacy rather than spontaneous physical urge. This model has been influential and has shaped how clinicians approach female sexual interest and arousal disorder (FSIAD).
However, critics argue Basson's model has been over-generalized. Brotto et al. (2016, Journal of Sexual Medicine) found that both spontaneous and responsive desire exist across diverse women, and that physical factors, including hormonal status, pelvic floor dysfunction, and medication side effects like SSRIs, contribute substantially to low libido across all age groups. The "emotional-first" framing, while useful clinically, shouldn't be used to dismiss physiological causes out of hand.
What did they get wrong (or right)?
She got the broad strokes right, and her epistemic humility is genuinely refreshing. Saying "I don't consider myself an expert" and then directing people to someone who is? That's exactly what a responsible clinician should do on a platform where overconfidence is the norm.
Where she's slightly off: the phrase "more emotional than physical for the most part" risks becoming a shorthand that dismisses hormonal and physiological contributors. For perimenopausal and postmenopausal women specifically, declining estrogen and testosterone levels have measurable effects on genital blood flow, vaginal tissue, and baseline arousal (Davis et al., 2019, Lancet Diabetes and Endocrinology). Framing libido loss primarily as an emotional problem in a video tagged "menopause" could inadvertently steer viewers away from legitimate hormonal evaluation.
Her point about medical training is, unfortunately, well-documented. A 2019 survey published in Sexual Medicine found that fewer than 30% of OB-GYN residency programs included structured curricula on female sexual dysfunction. She's not alone in that gap.
What should you actually know?
Low libido in women over 35 and through menopause is genuinely multifactorial, and no single explanation covers everyone. The emotional component is real and well-supported. So are the physical ones.
For perimenopausal women especially, hormonal shifts, specifically declining estradiol and testosterone, can reduce genital sensitivity, vaginal lubrication, and baseline sexual interest through direct physiological pathways. These aren't secondary to emotional factors; they can be primary drivers. The distinction matters because the treatment pathways differ. Cognitive and relational approaches work for emotionally rooted low desire. Hormonal evaluation and management, including options like low-dose testosterone therapy, which the FDA has not approved specifically for female libido but which is used off-label with a growing evidence base (Islam et al., 2019, Cochrane Database of Systematic Reviews), may be appropriate when physiology is the driver.
The takeaway: if you're experiencing low libido, a clinician who only asks about your relationship isn't doing the full job. Neither is one who only runs hormone panels. A thorough evaluation covers both.
Should you follow her referral to Dr. Kelly Casperson?
The referral itself is reasonable. Dr. Casperson is a board-certified urologist with documented clinical focus on female sexual health and is a recognized voice in the space. Recommending a specialist over selling a program yourself is the right call. That said, always verify any clinician's credentials, review scope of practice for your specific situation, and treat social media recommendations, even from well-intentioned physicians, as a starting point for research rather than a final answer.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
The 'Pause Life · TikTok creator
567.5K views on this video
Reply to @mchllbeauty_rn #libido #women #over35 #over40 #over35club #menopause #menopausalwomenoftiktok #aging #happy #relationship
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about basson (2001) established?
Basson (2001) established that many women experience 'responsive' rather than spontaneous desire, supporting the emotional component of female libido, but this model does not apply universally.
What does the video say about brotto et al. (2016, journal of sexual medicine) confirmed?
Brotto et al. (2016, Journal of Sexual Medicine) confirmed that both spontaneous and responsive desire exist across women, and physical factors including hormones and medications contribute significantly.
What does the video say about testosterone levels decline steadily in women from their 20s onward.?
Testosterone levels decline steadily in women from their 20s onward. A 2019 Cochrane review (Islam et al.) found low-dose testosterone improved sexual function in postmenopausal women, though no FDA-approved female testosterone product currently exists in the U.S.
What does the video say about fewer than 30% of ob-gyn residency programs in a 2019?
Fewer than 30% of OB-GYN residency programs in a 2019 Sexual Medicine survey included structured curricula on female sexual dysfunction, making the creator's admitted knowledge gap a systemic problem, not an individual failure.
What does the video say about shifren et al. (2008, obstetrics?
Shifren et al. (2008, Obstetrics and Gynecology) estimated that 26-43% of U.S. women experience low sexual desire depending on age group, confirming the scale of the issue the creator described.
What does the video say about for perimenopausal?
For perimenopausal and postmenopausal women specifically, declining estradiol affects genital blood flow and tissue sensitivity through direct physiological mechanisms, meaning emotional-only framings may delay appropriate hormonal evaluation.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by The 'Pause Life, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.